Benev (mfg Viol) Sylfirm X

RF Microneedling · Dual-wave (CW+pulsed) bipolar RF microneedling

CurrentFDA ClearedBe the first to review

What it's actually cleared for: Pulsed/CW RF microneedling cleared for electrocoagulation and hemostasis in dermatologic procedures

Last verified: August 6, 2026 · How we verify

New: $30k–$50k|Used: $12k–$25kmarket estimate, no email required

Save device

Bottom line

The clinical differentiator play in RF microneedling: its pulsed-wave mode gives a legitimate angle on melasma, rosacea, and redness that Morpheus8 and most competitors can't credibly claim. The dermatologist-favorite alternative in the category and arguably the safest RF-MN choice for heavy Fitzpatrick IV-VI patient bases. Consumer name recognition trails Morpheus8 badly — you'll spend marketing dollars educating patients instead of harvesting search demand.

Overview

Pulsed mode marketed for melasma/redness

How it works

The science

2MHz bipolar RF through a 25-pin microneedle array in two waveforms: continuous wave (CW) for conventional dermal heating, tightening, and scar remodeling, and ultra-short pulsed wave (PW) — the signature. Pulsed delivery is claimed to selectively affect abnormal vessels and the dermal-epidermal junction while sparing normal tissue: the mechanistic basis for treating melasma, rosacea, and post-inflammatory redness, where continuous heating can worsen pigment. Depth adjusts ~0.3-4.0mm; eight preset mode combinations cover wrinkles, scars, laxity, pigment, vascular concerns across all skin types.

Patented tech

The dual-wave (pulsed + continuous) RF delivery is the proprietary core — VIOL markets it as the first RF-MN system with both waveforms. In practice, a waveform-switching capability that changes how thermal energy accumulates — not different physics.

Origin

VIOL Co., Ltd., South Korea; Benev (Mission Viejo, CA) is exclusive US distributor.

FDA & regulatory status

FDA ClearedCleared via 510(k)

What it's actually cleared for:

Pulsed/CW RF microneedling cleared for electrocoagulation and hemostasis in dermatologic procedures

510(k) numbers

K200185; K213612

Regulatory data is compiled from public FDA 510(k) records and may lag recent clearances. Always confirm status with the manufacturer before purchase.

Treatment economics

What practices charge

~$700-1,200 face sessions; melasma/rosacea protocols sold as 3-4 session courses (~$2,000-4,000) spaced 4 weeks. Slightly less per session than Morpheus8 in most markets, but more frequent low-downtime protocols mean annualized revenue per patient can match or beat it.

Consumables & recurring cost

Single-use 25-pin tips (FDA-cleared versions via Benev) ~$75-150 each depending on volume. At 30 treatments/month, ~$27k-54k/year; avoid gray-market tips — they void support and create liability.

Ideal for

Best-fit practice

Dermatology-led practices and medspas with significant melasma, rosacea, and darker-skin-type demand — the segments other RF-MN devices handle worst. Also fits a "gentler, no-downtime" positioning against aggressive Morpheus8 marketing. Patients skew 30s-50s, pigment- and redness-driven.

Compliance

Medical director & delegation

Class II 510(k)-cleared RF microneedling requiring medical oversight; state rules vary — the melasma/vascular use cases warrant provider training beyond a weekend course.

Contraindications & screening

Implanted electronic devices, pregnancy, active infection or open lesions, recent isotretinoin, keloid tendency, uncontrolled diabetes or healing disorders. Melasma patients need realistic expectations and strict photoprotection — it improves, it doesn't cure.

Ownership

Warranty & service

~1-year warranty through Benev, extended negotiable at sale; post-warranty service runs through the distributor — get response-time commitments in writing.

Resale & used market

Used ~$25k-40k with improving liquidity as clinical reputation grows; smaller buyer pool than Morpheus8 but stable-to-firming — one of the few RF-MN devices gaining mindshare.